232 related articles for article (PubMed ID: 3665118)
1. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy.
Bevan JS; Adams CB; Burke CW; Morton KE; Molyneux AJ; Moore RA; Esiri MM
Clin Endocrinol (Oxf); 1987 May; 26(5):541-56. PubMed ID: 3665118
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
3. Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy.
Pelkonen R; Grahne B; Hirvonen E; Karonen SL; Salmi J; Tikkanen M; Valtonen S
Clin Endocrinol (Oxf); 1981 Apr; 14(4):335-48. PubMed ID: 7261416
[TBL] [Abstract][Full Text] [Related]
4. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
5. The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography.
Johnston DG; Hall K; Kendall-Taylor P; Ross WM; Crombie AL; Cook DB; Watson MJ
Clin Endocrinol (Oxf); 1986 Jun; 24(6):675-85. PubMed ID: 3098457
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine-unresponsive prolactin macroadenoma in a prepubertal female.
Cheyne KL; Lightner ES; Comerci GD
J Adolesc Health Care; 1988 Jul; 9(4):331-4. PubMed ID: 3417510
[TBL] [Abstract][Full Text] [Related]
7. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy.
Howlett TA; Wass JA; Grossman A; Plowman PN; Charlesworth M; Touzel R; Rees LH; Savage MO; Besser GM
Clin Endocrinol (Oxf); 1989 Feb; 30(2):131-40. PubMed ID: 2612015
[TBL] [Abstract][Full Text] [Related]
8. The management of pituitary tumours and post-operative visual deterioration.
Adams CB
Acta Neurochir (Wien); 1988; 94(3-4):103-16. PubMed ID: 3063070
[TBL] [Abstract][Full Text] [Related]
9. Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas.
Eversmann T; Fahlbusch R; Rjosk HK; von Werder K
Acta Endocrinol (Copenh); 1979 Nov; 92(3):413-27. PubMed ID: 574700
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
12. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1986 Nov; 25(5):561-72. PubMed ID: 3621623
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine.
Zárate A; Canales ES; Cano C; Pilonieta CJ
Acta Endocrinol (Copenh); 1983 Oct; 104(2):139-42. PubMed ID: 6356741
[TBL] [Abstract][Full Text] [Related]
14. Management of extra-sellar pituitary tumours with bromocriptine: comparison of prolactin secreting and non-functioning tumours using half-field visual evoked potentials and computerised tomography.
Pullan PT; Carroll WM; Chakera TM; Khangure MS; Vaughan RJ
Aust N Z J Med; 1985 Apr; 15(2):203-8. PubMed ID: 3861164
[TBL] [Abstract][Full Text] [Related]
15. Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy.
Belchetz PE; Carty A; Clearkin LG; Davis JC; Jeffreys RV; Rae PG
Clin Endocrinol (Oxf); 1986 Sep; 25(3):325-30. PubMed ID: 3791672
[TBL] [Abstract][Full Text] [Related]
16. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK
World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828
[TBL] [Abstract][Full Text] [Related]
18. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy.
Wass JA; Moult PJ; Thorner MO; Dacie JE; Charlesworth M; Jones AE; Besser GM
Lancet; 1979 Jul; 2(8133):66-9. PubMed ID: 87966
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of radiotherapy and bromocriptine treatment in patients with previous surgery for macroprolactinomas.
Moberg E; af Trampe E; Wersäll J; Werner S
Neurosurgery; 1991 Aug; 29(2):200-4; discussion 204-5. PubMed ID: 1886657
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
